CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 49 enrolled
Drug / intervention
Kenalog or placebo +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01692756
NCT01692756Phase 2Completed

Early Anti-inflammatory Treatment in Patients With Acute ACL Tear

Cale Jacobs·interventional·Posted Sep 25, 2012·Updated Dec 5, 2018

In Brief

A Phase 2 clinical trial evaluating Kenalog or placebo, Kenalog then Placebo, and 2 other interventions for Anterior Cruciate Ligament (ACL) Tears. Completed, enrolled 49 participants across 1 site.

Detailed Summary

This research study is the first of its kind and will allow health care professionals and researchers to answer many questions about the reasons why anterior cruciate ligament (ACL) injury leads to knee pain and disability and osteoarthritis. We also hope that this study will be the beginning of new, more powerful and safer drugs to help patients with ACL injuries heal sooner and return to sports or daily activities pain free. Study participants will be recruited from the University of Kentucky and Vanderbilt University. The purpose of this research is to gather information on how safe and effective Kenalog® is in alleviating knee pain following ACL rupture.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 25, 2012
Enrollment StartMar 1, 2013
Primary CompletionFeb 5, 2017
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 13.8 years ago

Interventions

Kenalog or placebodrug

Kenalog then Placebodrug

Kenalogdrug

Placebodrug